ASCO 2016 annual meeting

Many pivotal studies were presented during the ASCO 2016 Annual Meeting, held from June 3 till 7 in Chicago, IL. MediPaper summarised the key data of the ASCO 2016, with focus on immunotherapies. Do you know all the key results?

SaveSave

Posts

PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

There is no excerpt because this is a protected post.

ASCO 2016 ribociclib & abemaciclib Data - MediPaper Medical Communications

ASCO16 Ribociclib & Abemaciclib Data

There is no excerpt because this is a protected post.

ASCO 2016 Palbociclib Data MediPaper Medical Communications

ASCO16 palbociclib (Ibrance©) Data

There is no excerpt because this is a protected post.

ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

There is no excerpt because this is a protected post.

asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

There is no excerpt because this is a protected post.

ASCO2016 ipilimumab data - MediPaper Medical Communications

ASCO16 Ipilimumab (Yervoy©) Data

There is no excerpt because this is a protected post.

asco 2016 nivolumab medipaper medical communications

ASCO16 Nivolumab (Opdivo©) Data

There is no excerpt because this is a protected post.

asco 2016 pembrolizumab medipaper medical communications

ASCO16 Pembrolizumab (Keytruda©) Data

There is no excerpt because this is a protected post.